Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide vs Placebo Add-on to Insulin Glargine in T2D
NCT02152371Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2014
- Primary completion
- Oct 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 7
01
Overview
A Phase 3 trial of dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started May 2014; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02152371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152371.